Koji Hayashizaki

This inventor holds 3 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Chiba University, Eisai R&d Management Co., Ltd.. Active years: 2017-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Koji Hayashizaki. Retrieved from https://idiyas.com/inventor/koji-hayashizaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 (Patent Applications = 1)

% Patents Active = 66.7

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 6.0

ph-index = 1

Company Filing History:

Eisai R&d Management Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2017-2019

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10513561 - Anti-MYL9 antibody (2019-12-24),

2. 10100107 - Method for identifying a compound useful with myosin regulatory light chain polypeptide antibody for treatment of an inflammatory disease (2018-10-16),

3. 9758574 - Inflammatory disease treatment composition including anti-myosin regulatory light-chain polypeptide antibody (2017-09-12),

Title: Koji Hayashizaki: Innovator in Antibody Research

Introduction

Koji Hayashizaki is a prominent inventor based in Chiba, Japan. He has made significant contributions to the field of antibody research, holding a total of 3 patents. His work focuses on developing innovative solutions for medical applications, particularly in the treatment of inflammatory diseases.

Latest Patents

Hayashizaki's latest patents include an anti-MYL9 antibody, which provides a means to inhibit the interaction between Myl9 and CD69 in humans. This invention includes a pharmaceutical composition that utilizes this antibody. Additionally, he has developed a method for identifying compounds that can be used with myosin regulatory light chain polypeptide antibodies for treating inflammatory diseases. This method aims to suppress inflammatory responses by targeting the interaction between Myl and CD69.

Career Highlights

Throughout his career, Koji Hayashizaki has worked with notable institutions, including Chiba University and Eisai R&D Management Co., Ltd. His research has significantly advanced the understanding of antibody interactions and their potential therapeutic applications.

Collaborations

Hayashizaki has collaborated with esteemed colleagues such as Toshinori Nakayama and Hiroyuki Hosokawa. These partnerships have further enriched his research and contributed to the development of innovative medical solutions.

Conclusion

Koji Hayashizaki's work in antibody research exemplifies the impact of innovation in the medical field. His patents and collaborations highlight his commitment to advancing healthcare through scientific discovery.

Profile summary based on public USPTO records.